Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

JudicialWatch.org: Genital Herpes Three Times More Common in Blacks; polyDNA Recommends Gene-Eden-VIR Proven to Reduce Symptoms of a Herpes Infection
  • USA - English


News provided by

PolyDNA

Feb 01, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX


We recommend that individuals with an HSV-2 infection take Gene-Eden-VIR. This Herpes remedy was proven to reduce Genital Herpes symptoms in a post-marketing clinical study that followed FDA guidelines. - Mike Evans, polyDNA

Post this

Rochester, NY (PRWEB) February 01, 2014 -- Studies have shown that 50% of black women have Herpes, which is half of the women in the community. Among the general population, Genital Herpes is three times more prevalent among blacks compared to whites. “HSV-2 infection is more common among non-Hispanic blacks (39.2%) than among non-Hispanic whites (12.3%) or Mexican Americans (10.1%). This disparity remains even among persons with similar numbers of lifetime sexual partners. For example, among persons with 2-4 lifetime sexual partners, HSV-2 is still more prevalent among non-Hispanic blacks (34.3%).” (See the CDC’s website, last updated on February 13, 2013) (2). polyDNA recommends that the African American community consider Gene-Eden-VIR to help the immune system target the latent Herpes virus. This natural product was clinically proven to reduce Herpes symptoms in a study that followed FDA guidelines.

“Black women have the highest rate of infection and their rate is nearly twice as high as men. Overall, 21 percent of all women are infected, compared with 11.5 percent of men. For the black community, 39 percent of all African Americans are infected, compared with 12 percent for whites.” (See YourBlackWorld.net, from August 31, 2012) (3).

Dr. Kevin Fenton said: “Herpes remains a common and serious health threat in the United States. Everyone should be aware of the symptoms, risk factors and steps that can be taken to prevent the spread of this lifelong and incurable infection.” Dr. Fenton is the director of the CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention. (See CNN.com, from March 10, 2010) (4).

“Fenton said the high rate of Herpes among African-Americans is most likely contributing to the high rate of HIV in that community. In fact, statistics show that people with Herpes are two to three times more likely to get HIV if exposed (4).”

polyDNA points out that the CDC also estimates that more than 80 percent of the people who have the Herpes Simplex 2 virus don't know they are infected. “Many people never have symptoms or outbreaks, or those symptoms are mild and mistaken for something else. But transmission can occur without symptoms or visible sores (4).”

For those with a Genital Herpes infection, there are a number of treatments available. As a study reported, “Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day.” (See the journal Pharmacology & Pharmacy, from August 12, 2013) (5).

“We recommend that individuals with an HSV-2 infection take Gene-Eden-VIR. This Herpes remedy was proven to reduce Genital Herpes symptoms in a post-marketing clinical study that followed FDA guidelines.” Mike Evans, polyDNA

Individuals infected with the latent HSV-2 can ask their doctors about Gene-Eden-VIR, or they can go online to learn more. Gene-Eden-VIR is a safe, natural product that was proven to reduce genital herpes symptoms in a clinical study published in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs on August 12, 2013.

The study showed that Gene-Eden-VIR reduced genital herpes symptoms and was safe and effective (5). “Up to 70% of those studied reported a decrease in HSV-2 symptoms (5).”

Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of genital herpes (5).

Doctors can view the paper on Gene-Eden-VIR here: http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf.

To learn more about Gene-Eden-VIR and HPV, visit http://gene-eden-kill-virus.com/Herpes-Remedy.php. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

Reference:

(1) U.S. Rates of HSV-1 and HSV-2 Infection Are Falling, Especially Among Whites. Published on October 16, 2013.
http://www.jwatch.org/na33053/2013/12/11/us-rates-hsv-1-and-hsv-2-infection-are-falling-especially

(2) CDC - Genital Herpes - CDC Fact Sheet. Last updated on February 13, 2013.
http://www.cdc.gov/std/herpes/STDFact-herpes-detailed.htm

(3) CDC: Nearly Half of All Black Women Have Genital Herpes. Published on August 31, 2012.
http://www.yourblackworld.net/2012/08/uncategorized/cdc-nearly-half-of-all-black-women-have-genital-herpes/
(4) CDC says genital herpes is still a 'serious health threat'. Published march 10, 2010.
http://edition.cnn.com/2010/HEALTH/03/10/genital.herpes/

(5) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Mike Davis, PolyDNA, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.